Search research articles
Contact Us
Filters
Showing results (111-120 of 143) with videos related to
Page
of 15
Sort By:
Cancer Chemotherapy and Pharmacology
|
April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Ticiana B Leal, Scot C Remick, Chris H Takimoto, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Investigational New Drugs
|
May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
Pei Jye Voon, Eric X Chen, Helen X Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement
Edward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
Journal of the National Cancer Institute
|
December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
Brian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
Joseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B Allred, Li Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
Shivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 143) with videos related to
Sort By:
Page
of 15
Cancer Chemotherapy and Pharmacology
|
April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Ticiana B Leal, Scot C Remick, Chris H Takimoto, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Investigational New Drugs
|
May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
Pei Jye Voon, Eric X Chen, Helen X Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement
Edward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
Journal of the National Cancer Institute
|
December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
Brian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
Joseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B Allred, Li Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
Shivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.
Page
of 15